Search research articles
Contact Us
Filters
Showing results (11-20 of 27) with videos related to
Page
of 3
Sort By:
Cancer Research
|
May 15, 1992
Relationship of VP-16 to the classical multidrug resistance phenotype
M Sehested, E Friche, P B Jensen, et al.
British Journal of Cancer
|
February 1, 1993
Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells
E Friche, E J Demant, M Sehested, et al.
Biochemical Pharmacology
|
January 15, 1991
Cytosolic free Ca2+ in daunorubicin and vincristine resistant Ehrlich ascites tumor cells. Drug accumulation is independent of intracellular Ca2+ changes
P Bouchelouche, E Friche, M Sehested, et al.
Cancer Research
|
August 15, 1991
Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells
E Friche, M K Danks, C A Schmidt, et al.
Progress in Clinical and Biological Research
|
January 1, 1983
Mechanism of resistance to anthracyclines and vinca alkaloids
K Danø, T Skovsgaard, N I Nissen, et al.
Biochemical Pharmacology
|
June 17, 2000
Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposide
D Nielsen, C Maare, J Eriksen, et al.
Biochemical Pharmacology
|
June 1, 1990
In vitro circumvention of anthracycline--resistance in Ehrlich ascites tumour by anthracycline analogues
E Friche, P B Jensen, H Roed, et al.
Cancer Communications
|
January 1, 1990
The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor
E Friche, P B Jensen, M Sehested, et al.
British Journal of Cancer
|
July 1, 1990
Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells
M Sehested, T Skovsgaard, P B Jensen, et al.
Biochemical Pharmacology
|
August 3, 1993
Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16)
M Sehested, P B Jensen, B S Sørensen, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 27) with videos related to
Sort By:
Page
of 3
Cancer Research
|
May 15, 1992
Relationship of VP-16 to the classical multidrug resistance phenotype
M Sehested, E Friche, P B Jensen, et al.
British Journal of Cancer
|
February 1, 1993
Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells
E Friche, E J Demant, M Sehested, et al.
Biochemical Pharmacology
|
January 15, 1991
Cytosolic free Ca2+ in daunorubicin and vincristine resistant Ehrlich ascites tumor cells. Drug accumulation is independent of intracellular Ca2+ changes
P Bouchelouche, E Friche, M Sehested, et al.
Cancer Research
|
August 15, 1991
Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells
E Friche, M K Danks, C A Schmidt, et al.
Progress in Clinical and Biological Research
|
January 1, 1983
Mechanism of resistance to anthracyclines and vinca alkaloids
K Danø, T Skovsgaard, N I Nissen, et al.
Biochemical Pharmacology
|
June 17, 2000
Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposide
D Nielsen, C Maare, J Eriksen, et al.
Biochemical Pharmacology
|
June 1, 1990
In vitro circumvention of anthracycline--resistance in Ehrlich ascites tumour by anthracycline analogues
E Friche, P B Jensen, H Roed, et al.
Cancer Communications
|
January 1, 1990
The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor
E Friche, P B Jensen, M Sehested, et al.
British Journal of Cancer
|
July 1, 1990
Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells
M Sehested, T Skovsgaard, P B Jensen, et al.
Biochemical Pharmacology
|
August 3, 1993
Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16)
M Sehested, P B Jensen, B S Sørensen, et al.
Page
of 3